Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

NCT04197219 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI is leaving institution

Conditions

Recurrent Endometrial Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Axitinib

Sponsor

Case Comprehensive Cancer Center